focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
probably not many shares available at the lower prices.......they will definitely want the price at ..say..6p + to get some cash in from those 5p Options ...
Sold my remaining shares, good luck guys.
Really kicking on before the weekend……Lady Luck on the side of us holders
Nice to see chunkier buys coming in now.
" FDA decision date for Lupus phase 3 trial is due to be announced next week? "
Lambo
A Type C meeting date is due ....with the actual meeting to take place within 75 days from submission
27 March : " A Type C meeting with the FDA has been requested and the date of the meeting should be confirmed within the FDA guidelines of 21 days from submission which is expected to be within the FDA guidelines of 75 days from submission"
Well the price action based on volume is definitely on the upside……..anyone here thought due to the market cap some PE firm or Avion themselves might just want to scoop this up. The potential based on milestones is huge - that last RNS has really perked up interest. We aren’t looking at that far away either with the FDA meet taking place next month.
Cauldstream7,
What are you referring to ? I never said ´ current fundraising ´ … I said LAST fundraising
Fir the landstead warrants , all you have to do is read the RNS issued about the Last fund raising .
well its really nice to see SP pass my Target of 2.50p and looking like
it could attack the next level 3.20p within days if MM steady ship.
wildtiger at it again i see, he just can't keep quiet when he take profit LOL!!
he has to spread it
GL to him''
So there it is folks. All we can safely conclude is that NO-ONE has a clue where the price is heading. Which we kinda knew already, as it's always the case.
From these historically low levels. I personally feel a run to double digits is firmly in play
My gut feeling tells me not to be too greedy with this one. The whole market has gone up abit way too much despite all the issues around the world at the moment.
Sold today when FDA decision date for Lupus phase 3 trial is due to be announced next week? Historically the share price has climbed significantly leading up to the FDA meeting date and the price is at historically low levels, I would suggest the time to derisk would be before the FDA decision date by which time the price will likely be over 5p, but at least you kept some
Sold the all ones I bought from 1.9p, keeping some just in case. As always I'm happy for this to go either way from here
It’s called trading, bought back in at 2.4p average as the CIDP trial news is a game changer
28th March : It’s a Lanstead death spiral, what else do investors expect, will drift back to 1.5p range now as no news expected for a few months...the only way is down I’m afraid until they do a proper placing
13th April : Should get confirmation of the FDA decision date for the Lupus phase 2/3 trial funded by Avion for $25m within the next few days, as we build up to the date I can see this comfortably above 5p where the options will kick in,
14th April : If approvals are given this will be sat back above 10p imo and very much game on
Lambo
As usual... it appears the right side of your brain clearly doesn't know what the left side of your brain is doing .... or is it that the crystal ball you bought has turned out to be a dud ?
The meeting to get excited about is the FDA type C meeting to approve Lupozor phase 2/3 trial funded for $25m by Avion. We should get the date for this meeting early date meet assuming the date will be late May. If approvals are given this will be sat back above 10p imo and very much game on after a long spell out in the cold, a successful phase 3 trial and the Mcap here will be well north of £200m , all to play for
All I would not get too excited just yet as we know from past experience the type C meeting will take place 16th May it will then take the FDA at least 2 months to respond and then it will take several weeks for Imm and Avion to review and tell us what was said. Then there will be another review required to send to the FDA an amended request which may need another type C meeting. What would be nice to told by Imm and Avion is when will the Lupuzor P2/P3 start in H2. You would hope that they are getting a list of patients for the start of the trial. Am I expecting too much? If they said the preparation time will take 3/4 months as we have to get the right people on the trial then at least we have the facts. I did hope to also what progress had been made by Avion using Imm as a Europe outlet. At this moment in time Imm are still my Hmm until we are well into H2.
Nolupus:
What are you referring to " in the current fundraising". I have not heard of any current fundraising. And where is there any reference to the latest Lanstead and L1 warrants being exercisable at a price lower than 11p?
Extract from the last fund raising RNS ….
There remain outstanding 25,640,254 Options in the Company, held equally by L1 and Lind, which may be exercised at any time up to 10 June 2023, with an exercise price of 11 pence.
However, as the price at which shares are to be issued in the current fundraising is less than 11 pence, (the exercise price of the Options) the number of Options and the exercise price of Options held by L1 and Lind fall to be varied. The effect of the current fundraising is to amend the exercise price from 11 pence to 5 pence and to increase the number of Options held by L1 and Lind from 25,640,254 to 56,408,558.
** the landstead warrants have a 10 year expiry timescale **
oscar22 - no real need to add that disclaimer at the end. We'd kinda guessed you were more ramper, less "professional financial advisor".
The recent RNS from ImmuPharma has brought some truly exciting news regarding P140 clinical program for chronic idiopathic demyelinating polyneuropathy (CIDP). Immupharma has secured a pre-IND meeting date with the FDA for the Phase 2/3 adaptive study of P140 in CIDP, marking a game-changing milestone as it will be the first pivotal clinical study of P140 in patients with this rare neurological disease.
What's even more thrilling is that following the pre-IND meeting, Immupharma plans to submit an application for Orphan Drug status. If approved, Immupharma will enjoy 7 years of market exclusivity post-marketing approval, giving Immupharma a significant edge in the CIDP market. And here's the icing on the cake: the CIDP market is projected to reach a staggering US$2.7 billion in global sales by 2029, showcasing the immense potential of P140 in this space.
To shed some light on the difference between Lupuzor and P140: Lupuzor is a specific formulation of the P140 peptide that Immupharma has developed for treating systemic lupus erythematosus (SLE). On the other hand, P140 is a versatile platform with the potential to address various autoimmune and inflammatory conditions, including CIDP. Both Lupuzor and P140 share a groundbreaking mechanism of action that selectively corrects the biological mechanisms responsible for autoimmune and inflammatory conditions.
In a nutshell, the recent announcement by Immupharma regarding the P140 clinical program for CIDP is nothing short of exhilarating! With the potential revenue from the booming CIDP market and the pursuit of Orphan Drug status, the value of investments in Immupharma could soar to new heights. I look forward to hearing more updates on this promising development, as it could have a massive impact on the lives of CIDP patients and the growth of investments in this domain.
Disclaimer: This note is for informational purposes only and should not be construed as financial advice. Please consult a professional financial advisor before making any investment decisions.
L1 5p warrants expire in June I think be nice to get to 5p before FDA decision date shouldn’t be too difficult any volume and it will move up very quickly imo
Lordloadsoflolly,
They deserve them more than all the other warrant holders such as Landstead, L1 capital etc , imo
pokerchips - & both Tims fully deserve them. Not.
Should get confirmation of the FDA decision date for the Lupus phase 2/3 trial funded by Avion for $25m within the next few days, as we build up to the date I can see this comfortably above 5p where the options will kick in, FDA approval and we should be sat at 10p by early June imo, GL all holders we should be in for quite a ride